Using Tranexamic Acid to Reduce Platelet Transfusions in Stem Cell Transplant Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of using prophylactic oral and intravenous Tranexamic Acid (TXA) combined with therapeutic platelet transfusions in patients undergoing autologous hematopoietic stem cell transplantation (ASCT) for hematologic malignancies. The study aims to determine if this approach is safer and more effective than the standard practice of prophylactic platelet transfusions. By potentially reducing the need for platelet transfusions, the trial seeks to minimize the associated risks and complications while optimizing patient care. Participants will be monitored for bleeding events and platelet counts throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults 18 years or older undergoing ASCT for a hematologic malignancy
2. Patients providing written informed consent prior to starting transplantation

Exclusion Criteria:

1. A previous WHO grade 2, 3 or 4 bleeding event within the past year
2. A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis
3. A current provoked thrombotic event (e.g. catheter-related thrombosis) within last month and/or still requiring anticoagulant treatment.
4. A requirement for therapeutic anticoagulant or anti-platelet drugs during ASCT
5. Active angina (chest pain of presumed cardiac origin either at rest or with activity)
6. Current or previous (within 2 weeks) urinary tract bleeding
7. An inherited hemostatic or thrombotic disorder
8. Coagulopathy defined as a prothrombin time '/International Normalization Ratio (INR) or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L
9. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies (Refractoriness is defined as 2 consecutive ABO matched platelet transfusions with platelet increment of \< 7.5 and the presence of anti-HLA antibodies)
10. Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL/min/1.78m2)
11. Pregnant or breast-feeding
12. Unwilling or unable to provide informed consent
13. Participant has acquired disturbances to his/her colour vision (does not apply to congenital colour blindness)
14. Participant has known sensitivity or allergy to Tranexamic Acid or any of its ingredients

Where it's running

• Tom Baker Cancer Centre
  Calgary, Alberta, Canada Recruiting
• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting
• Eastern Regional Health Authority
  St. John's, Newfoundland and Labrador, Canada Recruiting
• Hamilton Health Sciences - Juravinski Hospital and Cancer Centre
  Hamilton, Ontario, Canada Recruiting
• London Health Sciences Centre
  London, Ontario, Canada Recruiting
• The Ottawa Hospital
  Ottawa, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Alan Tinmouth, MD — The Ottawa Hospital
• Study coordinator: Sohail Robert, RN
• Email: sorobert@ohri.ca
• Phone: 613-737-8899

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• KK2430 in people with hematologic cancers

  This study tests KK2430 in adults with blood-related cancers to see if it is safe and how it behaves in the body, with the goal of understanding its potential to help in treatment.

  Recruiting Phase 1/2 Kyowa Kirin Co., Ltd. · Greenville, South Carolina · NCT07629726

• JNJ-95804306 in relapsed or refractory blood cancers

  This study tests JNJ-95804306 in people with relapsed or refractory hematologic cancers to find a safe dose and see if it helps control the disease when given alone or with standard therapy.

  Recruiting at 19 sites Phase 1 Janssen Research & Development, LLC · Indianapolis, Indiana and 18 other locations · NCT07572006

• AI-written plain-language discharge summaries for people with blood and other cancers

  This project tests whether AI-written plain-language discharge letters help adults with hematologic or other cancers understand their diagnosis, treatment, and next steps better than the usual medical letter.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07519811

• Flu vaccine strategies for adults with blood cancers

  This study will test three different flu vaccines to see which gives the strongest antibody and T-cell responses in adults with blood cancers, including people after autologous stem cell transplant or CAR-T therapy.

  Recruiting Phase 3 Asan Medical Center · Seoul · NCT07485855

• Combining donor-derived anti-CD19 CAR-T cells with haploidentical transplant using post-transplant cyclophosphamide

  This trial tests whether giving donor-derived anti-CD19 CAR-T cells together with a haploidentical bone marrow transplant using post-transplant cyclophosphamide can help adults (18–75) with high‑risk CD19+ blood cancers.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07162038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.